High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Blood

Volumn 100, Issue 5, 2002, Pages 1559-1565

  Ladetto, Marco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u}   Corradini, Paolo ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Vallet, Sonia ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Benedetti, Fabio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Vitolo, Umberto ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Martelli, Maurizio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Brugiatelli, Maura ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Coser, Paolo ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Perrotti, Alessio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Majolino, Ignazio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Fioritoni, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Morandi, Sergio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Musso, Maurizio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Zambello, Renato ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Chisesi, Teodora ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Renzo, Nicola Di ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Vivaldi, Paolo ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   De Crescenzo, Alberto ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Gallamini, Andrea ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Salvi, Flavia ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Santini, Gino ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Boccomini, Carola ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Sorio, Marco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Astolfi, Monica ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Drandi, Daniela ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Pileri, Alessandro ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Tarella, Corrado ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   more..

^a MOLINETTE HOSPITAL   (Italy)

^b Ospedale S Giovanni Vecchio   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e POLICLINICO BORGO ROMA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ Division of Hematology   (Italy)

^j VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^k LA MADDALENA CANCER CENTER   (Italy)

^l SPIRITO SANTO HOSPITAL   (Italy)

^m MAGGIORE HOSPITAL   (Italy)

ⁿ Azienda Ospedaliera S Bortolo   (Italy)

^o SS Giovanni e Paolo Hospital   (Italy)

^p CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^q SANTA CHIARA HOSPITAL   (Italy)

^r S CROCE E CARLE HOSPITAL   (Italy)

^s C Arrigo Children's Hospital   (Italy)

^t UNIVERSITY OF GENOA   (Italy)

^u Cattedra di Ematologia   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036720509     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0621     Document Type: Article

References (55)

1. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
2. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation
3. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma
4. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
5. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
6. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
7. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
8. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
9. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma
10. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular nonHodgkin's lymphoma
11. Molecular basis for stem cell transplantation in indolent lymphomas
12. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies
13. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma
14. High-dose therapy and autologous bone marrow transplantation In patients with follicular lymphoma during first remission
15. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft
16. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial
17. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
18. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion
19. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma
20. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment
21. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
22. Long-term molecular follow-up in indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Durable molecular and clinical remission can be achieved only in follicular subtypes
23. National Cancer Institute sponsored study of classifications of nonHodgkin's lymphomas: Summary and description of a working formulation for clinical usage
24. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
25. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma
26. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases
27. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: Short intervals between drug courses severely impair progenitor mobilization
28. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], prednisone) for treatment of mediastinal lymphoblastic lymphoma
29. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
30. Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients
31. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: High tolerability with reversible cardiotoxicity
32. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
33. Nonparametric estimation from incomplete observations
34. Asymptotically efficient rank invariant test procedures
35. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
36. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
37. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes In B cell tumors
38. Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation
39. Molecular and clinical remissions in multiple myeloma: Role of autologous and transplantation of hematopoletic cells
40. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
41. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
42. Quality of life-adjusted survival analysis of high-dose therapy With autologous marrow transplantation versus sequential chemotherapy for patients with lymphoma in first complete remission
43. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
44. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
45. Successful In vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
46. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
47. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: Long-term analysis and future developments
48. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
49. Treatment of patients with low-grade B-cell lymphoma with the combination of anti-CD20 monoclonal antibody and CHOP chemotherapy
50. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
51. Phase I clinical and pharmacokinetic study of bcl-2 antisense ollgonucleotide therapy in patients with non-Hodgkin's lymphoma
52. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
53. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
54. Immunogenetic therapy for B-cell malignancies
55. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model